NissensonA.R.Hyporesponsiveness to erythropoietin: overviewPerit Dial Int1996; 16: 417–20.
2.
TarngD.C., ChenT.W., HuangT.P.Iron Metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients.Am J Nephrol1995; 15: 230–7.
3.
CarameloC.A., CannataJ.B., RodelesM.B.Mechanisms of aluminum-induced microcytosis: lessons from accidental aluminum intoxication.Kidney Int1995; 47: 164–8.
4.
TarngD.C., HuangT.P.Recombinant human erythropoietin resistance in iron-deplete hemodialysis patients: role of aluminum toxicity.Am J Nephrol1996 (in press).
5.
TarngD.C., HuangT.P., ChenT.W.Resistance to recombinant human erythropoietin treatment in thalassaemic patients on chronic haemodialysis: a real clinical entity?Nephrol Dial Transplant1996; 11: 1893–5.
6.
GochJ., BirgegardG., DanielsonB.G.Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test.Nephron1996; 73: 403Nephrol Dial Transplant 1996; 73: 403–6.
7.
TinawiM., MartinK.J., BastaniB.Oral iron absorption test in patients on CAPD: comparison of ferrous sulfate and a polysaccharide ferric complex.Nephron1996; 74: 291–4.
